Torsdag 24 April | 21:43:00 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-20 08:00 Bokslutskommuniké 2025
2025-08-22 08:00 Kvartalsrapport 2025-Q2
2025-05-19 N/A X-dag ordinarie utdelning BIOWKS 0.00 SEK
2025-05-16 N/A Årsstämma
2025-02-21 - Bokslutskommuniké 2024
2024-08-02 - Kvartalsrapport 2024-Q2
2024-07-29 - Extra Bolagsstämma 2024
2024-05-27 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2024-05-24 - Årsstämma
2024-02-19 - Bokslutskommuniké 2023
2023-08-18 - Kvartalsrapport 2023-Q2
2023-05-29 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2023-05-26 - Årsstämma
2023-02-17 - Bokslutskommuniké 2022
2022-08-19 - Kvartalsrapport 2022-Q2
2022-05-23 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2022-05-20 - Årsstämma
2022-05-06 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2022-02-18 - Bokslutskommuniké 2021
2021-11-25 - Extra Bolagsstämma 2021
2021-08-20 - Kvartalsrapport 2021-Q2
2021-05-24 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2021-05-21 - Årsstämma
2021-02-19 - Bokslutskommuniké 2020
2020-08-21 - Kvartalsrapport 2020-Q2
2020-05-18 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2020-05-15 - Årsstämma
2020-02-14 - Bokslutskommuniké 2019
2019-10-18 - Kvartalsrapport 2019-Q3
2019-08-23 - Kvartalsrapport 2019-Q2
2019-05-27 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2019-05-17 - Årsstämma
2019-04-29 - Kvartalsrapport 2019-Q1
2019-02-22 - Bokslutskommuniké 2018
2018-08-19 - Kvartalsrapport 2018-Q2
2018-05-21 - X-dag ordinarie utdelning BIOWKS 0.00 SEK
2018-05-18 - Årsstämma
2018-02-19 - Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriBioteknik
Bio-Works Technologies är verksamt inom bioteknik. Bolaget utvecklar produkter som separerar och renar molekyler vid framställning av läkemedel. Teknologin baseras på kromatografi som har som avsikt att hantera läkemedelssubstansen. Kunderna återfinns inom den europeiska marknaden där produkterna säljs via distributionspartners och till bolag inom läkemedelsindustrin, samt forskningsinstitut och universitet. Bolaget bildades 2006 och har sitt huvudkontor i Uppsala.
2023-05-26 09:42:00

Bio-Works Technologies’ annual general meeting was held 26 May 2023. The following resolutions were made at the annual general meeting, among other resolutions.

The meeting adopted the income statement and balance sheet and the consolidated income statement and consolidated balance sheet for the financial year 2022.

The meeting resolved that no dividend shall be paid for the financial year 2022.

The meeting granted the board members and CEO discharge from liability for the financial year 2022.

The meeting resolved that the number of board members shall be four and re-elected Peter von Ehrenheim, Kirsti Gjellan, Peter Nählstedt and Johan Sedihn. Peter von Ehrenheim was re-elected as chairman of the board. The meeting resolved that directors’ fees of SEK 260,000 shall be paid to the chairman of the board and SEK 130,000 to each of the other directors not employed by the company. In addition to director fees’, no fees shall be paid for work in the board’s committees.

Öhrlings PricewaterhouseCoopers AB was re-elected as auditor. Leonard Daun will continue as the auditor in charge. The auditor's fee shall be paid in accordance with approved account.

In accordance with the board’s proposal, the meeting resolved to introduce a long-term warrant-based incentive program, for senior executives and key employees. The meeting resolved on an issue of a maximum of 200,000 warrants for this purpose. The warrants are issued at a price corresponding to the warrants' market value at the time of subscription calculated according to the Black & Scholes' model. The subscription price per share shall correspond to 125 percent of the volume-weighted average price paid for the company's share during a period of time after the meeting. Each warrant entitles the holder to subscribe for one new share in the company during the period 1 June 2026 – 30 June 2026. If all warrants are utilized for subscription, 200,000 new shares may be issued, corresponding to a dilution of approximately 0.57 percent of the total number of shares and votes in the company. The purpose of the program is, i.a., to encourage shareholding among senior executives and key employees, to increase their motivation to achieve or exceed the company's financial targets and to retain and recruit important people.

The meeting also resolved, in accordance with the board’s proposal, to insert a new paragraph in the articles of association to enable the board to collect power of attorneys and to allow postal voting prior to annual general meetings.

The meeting resolved, in accordance with the board’s proposal, to authorize the board for the period until the next annual general meeting, on one or more occasions, with or without preferential rights for shareholders, to decide on issue of new shares. The authorization includes shares corresponding to a maximum of ten (10) percent of the total number of issued shares in the Company at the time when the board first utilizes the authorization. The purpose of the authorization is to increase the company’s financial flexibility and the board’s margin for manoeuvre. If the board decides to issue shares with deviation from the shareholders' preferential rights, the reason shall be to broaden the owner circle, raise working capital, acquire companies or businesses or to acquire capital for such acquisitions.

The annual general meeting minutes, including complete resolutions, will shortly be published on the company’s website.